Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.
Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure.
复制标题
前列腺癌中的神经内分泌分化：辐射抗性和治疗衰竭的机制。
DOI：
10.3389/fonc.2015.00090
复制
发表时间：
2015
影响因子：
4.7
通讯作者：
Huang J
中科院分区：
文献类型：
--
作者：
Hu CD;Choo R;Huang J
前列腺癌的神经内分泌分化（NED）是前列腺癌细胞向神经内分泌样（NE-like）细胞转分化的一种公认的表型变化。ne样细胞缺乏雄激素受体和前列腺特异性抗原的表达，对治疗有抵抗性。此外，ne样细胞分泌肽激素和生长因子，以旁分泌方式支持周围肿瘤细胞的生长。越来越多的证据表明，NED与疾病进展和预后不良有关。包括雄激素剥夺疗法、化疗药物和放疗在内的治疗药物也会诱导NED，这一事实进一步支持了NED在前列腺癌进展和治疗反应中的重要性。我们将回顾支持治疗诱导的NED是治疗耐药机制的总体假设的工作，并讨论治疗诱导的NED与治疗诱导的衰老、上皮-间质转化和癌症干细胞之间的关系。此外，我们将以辐射诱导的NED为模型，探索几种基于NED的靶向策略，以开发新的治疗方法。最后，我们提出未来的研究将专门针对治疗诱导的NED，希望能够开发出更好的前列腺癌治疗方案。
Neuroendocrine differentiation (NED) in prostate cancer is a well-recognized phenotypic change by which prostate cancer cells transdifferentiate into neuroendocrine-like (NE-like) cells. NE-like cells lack the expression of androgen receptor and prostate specific antigen, and are resistant to treatments. In addition, NE-like cells secrete peptide hormones and growth factors to support the growth of surrounding tumor cells in a paracrine manner. Accumulated evidence has suggested that NED is associated with disease progression and poor prognosis. The importance of NED in prostate cancer progression and therapeutic response is further supported by the fact that therapeutic agents, including androgen-deprivation therapy, chemotherapeutic agents, and radiotherapy, also induce NED. We will review the work supporting the overall hypothesis that therapy-induced NED is a mechanism of resistance to treatments, as well as discuss the relationship between therapy-induced NED and therapy-induced senescence, epithelial-to-mesenchymal transition, and cancer stem cells. Furthermore, we will use radiation-induced NED as a model to explore several NED-based targeting strategies for development of novel therapeutics. Finally, we propose future studies that will specifically address therapy-induced NED in the hope that a better treatment regimen for prostate cancer can be developed.
登录
查看更多内容
影响因子：
45.3
作者：
D'Amico, Anthony V.;Chen, Ming-Hui;Kantoff, Philip W.
通讯作者：
Kantoff, Philip W.
影响因子：
4.8
作者：
Cox, ME;Deeble, PD;Parsons, SJ
通讯作者：
Parsons, SJ
影响因子：
3.9
作者：
Berruti, A;Mosca, A;Dogliotti, L
通讯作者：
Dogliotti, L
影响因子：
2.1
作者：
D'Amico, AV
通讯作者：
D'Amico, AV
影响因子：
8
作者：
Berenguer, C.;Boudouresque, F.;Ouafik, L'Houcine
通讯作者：
Ouafik, L'Houcine